ADB-FUBIATA

Overview

ADB-FUBIATA is a synthetic cannabinoid that belongs to the indazole-3-carboxamide family. It is a designer drug that has been used in recreational drugs and is often found in synthetic cannabis products. ADB-FUBIATA is known for its potent agonistic activity at the cannabinoid receptors, particularly CB1 and CB2.

Chemical structure of ADB-FUBIATA

Chemical Structure

ADB-FUBIATA is characterized by its indazole core, which is substituted at the 1-position with a carboxamide group. The chemical structure includes a tert-butyl group and a fluorobenzyl moiety, which contribute to its high affinity for cannabinoid receptors. The full chemical name is N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide.

Pharmacology

As a potent agonist of the cannabinoid receptors, ADB-FUBIATA mimics the effects of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. It binds to the CB1 and CB2 receptors, leading to a range of effects including euphoria, altered perception, and relaxation. However, due to its synthetic nature, the effects can be unpredictable and may include severe adverse reactions.

Legal Status

The legal status of ADB-FUBIATA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. It is often included in legislation targeting synthetic cannabinoids and "new psychoactive substances" (NPS).

Health Risks

The use of ADB-FUBIATA is associated with significant health risks. Users may experience tachycardia, hypertension, nausea, vomiting, and anxiety. In severe cases, it can lead to psychosis, seizures, and renal failure. The variability in synthetic cannabinoid products makes it difficult to predict the specific effects and risks associated with ADB-FUBIATA.

Related Pages

• Synthetic cannabinoids
• Cannabinoid receptor
• Recreational drug
• New psychoactive substances